NEWS OVERVIEW:

The Food and Drug Administration is ending its long-standing two-study requirement for new drug approvals to speed access to medicines. The policy shift reflects advances in scientific precision and existing trends toward relying on single trials. Implementation of the change will determine its impact on drug development timelines.

Some details for the context:

  • The FDA’s “default position” will now typically require one robust study plus supporting data for new drug approvals. :contentReference[oaicite:0]{index=0}
  • FDA Commissioner Dr. Marty Makary and his deputy outlined the change in a New England Journal of Medicine article. :contentReference[oaicite:1]{index=1}
  • The two-study standard dates back to the 1960s, originally aimed at confirming trial reproducibility. :contentReference[oaicite:2]{index=2}
  • FDA officials say advances in science make dual trials unnecessary in many cases, especially for common diseases. :contentReference[oaicite:3]{index=3}
  • The new policy could accelerate access to treatments but details on implementation and effects remain unclear. :contentReference[oaicite:4]{index=4}

Read the full story here


Keep Reading